{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:54:49Z","timestamp":1794304489120,"version":"4.9.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"DOI":"10.13039\/100015728","name":"Clinical Science Research and Development","doi-asserted-by":"crossref","award":["CX000570-13"],"award-info":[{"award-number":["CX000570-13"]}],"id":[{"id":"10.13039\/100015728","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Office of Research and Development","award":["CIN 24-128"],"award-info":[{"award-number":["CIN 24-128"]}]},{"DOI":"10.13039\/100017618","name":"Division of Diabetes, Endocrinology, and Metabolic Diseases","doi-asserted-by":"crossref","award":["P30DK092986"],"award-info":[{"award-number":["P30DK092986"]}],"id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Unknown if addition of newer diabetes medications is associated with kidney disease among older patients who were under recruited in clinical trials.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>In this target trial emulation, we report a protective association for kidney events and death for both glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor, compared with dipeptidyl peptidase-4 inhibitor.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The association of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor on kidney disease extended across multiple subgroups including short duration of use and in the older population.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A trial emulation approach evaluated kidney outcomes for addition of three diabetes medications among Veterans, including older Veterans underrepresented in trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort of Veterans with diabetes who were new users adding glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter 2 inhibitors (SGLT2is), or dipeptidyl peptidase-4 inhibitors (DPP4is). Each group was followed until a composite of death or kidney event defined as a 50% decline in eGFR, kidney failure (transplant or dialysis) or censored for nonpersistence of drug class, loss of follow-up, and study end. The primary analysis used propensity score weights to compare the hazard of the composite outcome. The secondary analysis considered cause-specific hazard of kidney events with death as censoring. An Aalen\u2013Johansen plot displayed individual outcomes of kidney event or death as a competing risk. Subgroup analyses evaluated Veterans by duration of use, age, eGFR, and urine protein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After propensity score weighting, the cohort included 42,684 GLP-1 RA, 44,198 SGLT2i, and 44,213 DPP4i episodes. The median age was 69 years, diabetes duration was 10.6 years (6.8\u201315.2), and eGFR was 75 ml\/min per 1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      (58\u201392). Event rates per 1000 person-years were 34.6 (33.3\u201336.0) versus 29.0 (27.8\u201330.3) versus 47.4 (46.0\u201348.9) for GLP-1 RA, SGLT2i, and DPP4i, respectively. There was a protective association for composite of kidney event and death for GLP-1 RA, hazard ratio (HR) 0.70 (0.67 to 0.74), and SGLT2i users (HR, 0.65 [0.61 to 0.68]) versus DPP4i. The results were similar for the cause-specific hazard of kidney event alone GLP-1 RA (HR, 0.72 [0.65 to 0.80]) and SGLT2i (HR, 0.48 [0.43 to 0.55]) and for subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GLP-1 RA and SGLT2i as add-on diabetes treatment were associated with lower composite and individual outcomes of kidney event and death. The association was similar across subgroups highlighting the value in primary prevention among older populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Podcast<\/jats:title>\n                    <jats:p>This article contains a podcast at https:\/\/dts.podtrac.com\/redirect.mp3\/www.asn-online.org\/media\/podcast\/CJASN\/2026_06_17_CJASNJune.21.6.6172.mp3<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.0000001033","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:02:23Z","timestamp":1774540943000},"page":"997-1009","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Target Trial Emulation"],"prefix":"10.2215","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3203-1608","authenticated-orcid":false,"given":"Adriana","family":"Hung","sequence":"first","affiliation":[{"name":"Veteran Administration Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center (GRECC), Veterans' Wellbeing through Innovation, Systems Science and Experience in Learning Health Systems (VETWISE-LHS), Nashville, Tennessee"},{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6849-6255","authenticated-orcid":false,"given":"Cole","family":"Beck","sequence":"additional","affiliation":[{"name":"Veteran Administration Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center (GRECC), Veterans' Wellbeing through Innovation, Systems Science and Experience in Learning Health Systems (VETWISE-LHS), Nashville, Tennessee"},{"name":"Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1821-3544","authenticated-orcid":false,"given":"Robert A.","family":"Greevy","sequence":"additional","affiliation":[{"name":"Veteran Administration Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center (GRECC), Veterans' Wellbeing through Innovation, Systems Science and Experience in Learning Health Systems (VETWISE-LHS), Nashville, Tennessee"},{"name":"Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0164-6589","authenticated-orcid":false,"given":"Amber J.","family":"Hackstadt","sequence":"additional","affiliation":[{"name":"Veteran Administration Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center (GRECC), Veterans' Wellbeing through Innovation, Systems Science and Experience in Learning Health Systems (VETWISE-LHS), Nashville, Tennessee"},{"name":"Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1651-8387","authenticated-orcid":false,"given":"Tom A.","family":"Elasy","sequence":"additional","affiliation":[{"name":"Veteran Administration Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center (GRECC), Veterans' Wellbeing through Innovation, Systems Science and Experience in Learning Health Systems (VETWISE-LHS), Nashville, Tennessee"},{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6555-2055","authenticated-orcid":false,"given":"Christianne L.","family":"Roumie","sequence":"additional","affiliation":[{"name":"Veteran Administration Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center (GRECC), Veterans' Wellbeing through Innovation, Systems Science and Experience in Learning Health Systems (VETWISE-LHS), Nashville, Tennessee"},{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"B1-20260618","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract."},{"issue":"10105","key":"B3-20260618","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet."},{"issue":"3 suppl 1","key":"B4-20260618","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2019.01.001","article-title":"US renal data system 2018 annual data report: epidemiology of kidney disease in the United States","volume":"73","author":"Saran","year":"2019","journal-title":"Am J Kidney Dis."},{"issue":"7","key":"B5-20260618","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med."},{"issue":"22","key":"B6-20260618","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med."},{"issue":"15","key":"B7-20260618","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"4","key":"B8-20260618","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int."},{"issue":"2","key":"B9-20260618","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"7","key":"B10-20260618","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","article-title":"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial","volume":"37","year":"2022","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"B11-20260618","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12877-018-0732-4","article-title":"Diabetic kidney disease in the elderly: prevalence and clinical correlates","volume":"18","author":"Russo","year":"2018","journal-title":"BMC Geriatr."},{"issue":"4S","key":"B12-20260618","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"de Boer","year":"2020","journal-title":"Kidney Int."},{"issue":"4","key":"B13-20260618","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamainternmed.2024.8129","article-title":"Emulating a target trial using observational data","volume":"185","author":"Dib","year":"2025","journal-title":"JAMA Intern Med."},{"issue":"24","key":"B14-20260618","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA."},{"key":"B15-20260618","doi-asserted-by":"crossref","first-page":"e087179","DOI":"10.1136\/bmj-2025-087179","article-title":"Transparent reporting of observational studies emulating a target trial: the TARGET statement","volume":"390","author":"Cashin","year":"2025","journal-title":"BMJ."},{"issue":"451","key":"B17-20260618","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/01621459.2000.10474263","article-title":"Estimating and using propensity scores with partially missing data","volume":"95","author":"D\u2019Agostino","year":"2000","journal-title":"J Am Stat Assoc."},{"issue":"2","key":"B18-20260618","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1515\/ijb-2012-0030","article-title":"A weighting analogue to pair matching in propensity score analysis","volume":"9","author":"Li","year":"2013","journal-title":"Int J Biostat."},{"issue":"3","key":"B19-20260618","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology."},{"issue":"12","key":"B20-20260618","first-page":"1946","article-title":"Comparing the performance of propensity score methods in healthcare database studies with rare outcomes","volume":"36","author":"Franklin","year":"2017","journal-title":"Stat Med."},{"issue":"3","key":"B21-20260618","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika."},{"issue":"27","key":"B22-20260618","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting fine-gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med."},{"issue":"3","key":"B23-20260618","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous markov chains based on censored observations","volume":"5","author":"Aalen","year":"1978","journal-title":"Scand J Stat."},{"issue":"1","key":"B24-20260618","doi-asserted-by":"crossref","first-page":"2217287","DOI":"10.1080\/0886022X.2023.2217287","article-title":"Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis","volume":"45","author":"Liu","year":"2023","journal-title":"Ren Fail."},{"issue":"9","key":"B25-20260618","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/17512433.2023.2247977","article-title":"Sodium-glucose cotransporter 2 inhibitors in frail, older people with type 2 diabetes and heart failure: do we have enough evidence to confidently support the use?","volume":"16","author":"Koufakis","year":"2023","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"4","key":"B26-20260618","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med."},{"issue":"7","key":"B27-20260618","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/gerona\/glab071","article-title":"Updating and validating the U.S. Veterans Affairs frailty index: transitioning from ICD-9 to ICD-10","volume":"76","author":"Cheng","year":"2021","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"5","key":"B28-20260618","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","article-title":"Website and R package for computing E-values","volume":"29","author":"Mathur","year":"2018","journal-title":"Epidemiology."},{"issue":"10193","key":"B29-20260618","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"issue":"10166","key":"B30-20260618","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet."},{"issue":"4","key":"B31-20260618","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med."},{"issue":"16","key":"B32-20260618","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJMc2112411","article-title":"Empagliflozin and major renal outcomes in heart failure","volume":"385","author":"Packer","year":"2021","journal-title":"N Engl J Med."},{"issue":"10454","key":"B33-20260618","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet."},{"issue":"7","key":"B34-20260618","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","journal-title":"Nat Med."},{"issue":"4","key":"B35-20260618","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol."},{"issue":"8","key":"B36-20260618","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.3390\/cells10081958","article-title":"The impact of glucose-lowering drugs on sarcopenia in type 2 diabetes: current evidence and underlying mechanisms","volume":"10","author":"Massimino","year":"2021","journal-title":"Cells."},{"issue":"1","key":"B37-20260618","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10654-018-0447-z","article-title":"A comparison of different methods to handle missing data in the context of propensity score analysis","volume":"34","author":"Choi","year":"2019","journal-title":"Eur J Epidemiol."},{"issue":"3","key":"B38-20260618","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/00273171.2024.2307529","article-title":"Propensity score weighting with missing data on covariates and clustered data structure","volume":"59","author":"Liu","year":"2024","journal-title":"Multivariate Behav Res."}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:03Z","timestamp":1786369323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.0000001033"}},"subtitle":["Glucagon-Like Peptide-1 Receptor Agonist, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors for Kidney Outcome Prevention"],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.0000001033","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"2025-05-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}